David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results. – How will this affect clinicians today?
INO-5401 and INO-9012 in combination with cemiplimab REGN2810 – Will this data effect clinicians today? – David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #glioblastoma
By Editor